Ranolazine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318652

CAS#: 95635-56-6 (HCl)

Description: Ranolazine is an anti-ischemic compound, which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Ranolazine HCl is a salt form of Ranolazine.


Chemical Structure

img
Ranolazine HCl
CAS# 95635-56-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 318652
Name: Ranolazine HCl
CAS#: 95635-56-6 (HCl)
Chemical Formula: C24H35Cl2N3O4
Exact Mass: 0.00
Molecular Weight: 500.460
Elemental Analysis: C, 57.60; H, 7.05; Cl, 14.17; N, 8.40; O, 12.79

Price and Availability

Size Price Availability Quantity
1g USD 350 2 weeks
5g USD 950 2 weeks
Bulk inquiry

Related CAS #: 95635-55-5 (free base)   95635-56-6 (HCl)    

Synonym: RS 43285; RS-43285; RS43285; CVT-303; CVT 303; CVT303; Ranolazine; Ranexa; Latixa; Ranexa; Ranolazine Dihydrochloride; Ranolazine HCl; Ranolazine Hydrochloride.

IUPAC/Chemical Name: N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride

InChi Key: RJNSNFZXAZXOFX-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H

SMILES Code: O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#95635-55-5 (Ranolazine free base). CAS# 95635-56-6 (Ranolazine HCl)

Product Data:
Biological target: Ranolazine dihydrochloride is an antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late INa and IKr currents.
In vitro activity: This study suggests that ranolazine could block multiple ion currents such as I(Na) and I(K(IR)) and suggests that these actions may contribute to some of the functional activities of neurons and endocrine or neuroendocrine cells in vivo. Reference: J Pharmacol Sci. 2009 Jul;110(3):295-305. https://pubmed.ncbi.nlm.nih.gov/19609066/
In vivo activity: This study found that animals with hypothyroidism have increased susceptibility to developing arrhythmia.Ranolazine is able to correct the arrhythmic phenotype. Reference: Life Sci. 2022 Nov 1;308:120945. https://pubmed.ncbi.nlm.nih.gov/36096245/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 20.0 39.96
DMF 20.0 39.96
Water 20.0 39.96

Preparing Stock Solutions

The following data is based on the product molecular weight 500.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. da Silva MV, Santos-Miranda A, Joviano-Santos JV, Souza DS, Marques LP, Sarmento JO, Beserra SS, Roman-Campos D. The insecticide β-Cyfluthrin induces acute arrhythmic cardiotoxicity through interaction with NaV1.5 and ranolazine reverses the phenotype. Clin Sci (Lond). 2022 Mar 18;136(5):329-343. doi: 10.1042/CS20211151. PMID: 35190819. 2. Chen BS, Lo YC, Peng H, Hsu TI, Wu SN. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells. J Pharmacol Sci. 2009 Jul;110(3):295-305. doi: 10.1254/jphs.09018fp. PMID: 19609066. 3. Han QJ, Forfia P, Vaidya A, Ramani G, deKemp RA, Mach RH, Mankoff DA, Bravo PE, DiCarli M, Chan SY, Waxman AB, Han Y. Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study. Front Cardiovasc Med. 2023 Jun 13;10:1118796. doi: 10.3389/fcvm.2023.1118796. PMID: 37383703; PMCID: PMC10293744. 4. Souza DS, Marques LP, Costa AD, Cruz JS, Rhana P, Santos-Miranda A, Joviano-Santos JV, Durço AO, Vasconcelos CML, Roman-Campos D. Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype. Life Sci. 2022 Nov 1;308:120945. doi: 10.1016/j.lfs.2022.120945. Epub 2022 Sep 9. PMID: 36096245.
In vitro protocol: 1. da Silva MV, Santos-Miranda A, Joviano-Santos JV, Souza DS, Marques LP, Sarmento JO, Beserra SS, Roman-Campos D. The insecticide β-Cyfluthrin induces acute arrhythmic cardiotoxicity through interaction with NaV1.5 and ranolazine reverses the phenotype. Clin Sci (Lond). 2022 Mar 18;136(5):329-343. doi: 10.1042/CS20211151. PMID: 35190819. 2. Chen BS, Lo YC, Peng H, Hsu TI, Wu SN. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells. J Pharmacol Sci. 2009 Jul;110(3):295-305. doi: 10.1254/jphs.09018fp. PMID: 19609066.
In vivo protocol: 1. Han QJ, Forfia P, Vaidya A, Ramani G, deKemp RA, Mach RH, Mankoff DA, Bravo PE, DiCarli M, Chan SY, Waxman AB, Han Y. Effects of ranolazine on right ventricular function, fluid dynamics, and metabolism in patients with precapillary pulmonary hypertension: insights from a longitudinal, randomized, double-blinded, placebo controlled, multicenter study. Front Cardiovasc Med. 2023 Jun 13;10:1118796. doi: 10.3389/fcvm.2023.1118796. PMID: 37383703; PMCID: PMC10293744. 2. Souza DS, Marques LP, Costa AD, Cruz JS, Rhana P, Santos-Miranda A, Joviano-Santos JV, Durço AO, Vasconcelos CML, Roman-Campos D. Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype. Life Sci. 2022 Nov 1;308:120945. doi: 10.1016/j.lfs.2022.120945. Epub 2022 Sep 9. PMID: 36096245.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P,
Belardinelli L, Henry RH. Effect of ranolazine on glycaemic control in patients
with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes
Metab. 2016 May;18(5):463-74. doi: 10.1111/dom.12629. Epub 2016 Feb 23. PubMed
PMID: 26749407.


2: Hartmann N, Mason FE, Braun I, Pabel S, Voigt N, Schotola H, Fischer TH,
Dobrev D, Danner BC, Renner A, Gummert J, Belardinelli L, Frey N, Maier LS,
Hasenfuss G, Sossalla S. The combined effects of ranolazine and dronedarone on
human atrial and ventricular electrophysiology. J Mol Cell Cardiol. 2016 Apr 4.
pii: S0022-2828(16)30059-1. doi: 10.1016/j.yjmcc.2016.03.012. [Epub ahead of
print] PubMed PMID: 27056421.


3: Cacciapuoti F. Ranolazine and Ivabradine: two different modalities to act
against ischemic heart disease. Ther Adv Cardiovasc Dis. 2016 Apr;10(2):98-102.
doi: 10.1177/1753944716636042. Epub 2016 Mar 3. Review. PubMed PMID: 26944071.


4: Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Jiang RH, Li X, Perry TD, Avila
B, Wang WQ, Hirakawa R, Smith-Maxwell C, Wu L, Dhalla AK, Rajamani S, Mollova N,
Stafford B, Tang J, Belardinelli L, Zablocki JA. Discovery of triazolopyridinone
GS-462808, a late sodium current inhibitor (Late I(Na)i) of the cardiac Na(v)1.5
channel with improved efficacy and potency relative to ranolazine. Bioorg Med
Chem Lett. 2016 Mar 26. pii: S0960-894X(16)30328-6. doi:
10.1016/j.bmcl.2016.03.096. [Epub ahead of print] PubMed PMID: 27038498.


5: Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to
evaluate the economic value of ranolazine for the symptomatic treatment of
chronic angina pectoris. Int J Cardiol. 2016 Mar 2;211:105-111. doi:
10.1016/j.ijcard.2016.02.140. [Epub ahead of print] Review. PubMed PMID:
26994453.


6: Saad M, Mahmoud A, Elgendy IY, Richard Conti C. Ranolazine in Cardiac
Arrhythmia. Clin Cardiol. 2016 Mar;39(3):170-8. doi: 10.1002/clc.22476. Epub 2015
Oct 13. Review. PubMed PMID: 26459200.


7: Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Notte GT, Kalla R, Jiang RH, Li
X, Perry TD, Avila B, Wang WQ, Smith-Maxwell C, Dhalla AK, Rajamani S, Stafford
B, Tang J, Mollova N, Belardinelli L, Zablocki JA. Discovery of triazolopyridine
GS-458967, a late sodium current inhibitor (Late I(Na)i) of the cardiac Na(V) 1.5
channel with improved efficacy and potency relative to ranolazine. Bioorg Med
Chem Lett. 2016 Mar 30. pii: S0960-894X(16)30331-6. doi:
10.1016/j.bmcl.2016.03.101. [Epub ahead of print] PubMed PMID: 27080178.


8: Lee JC, Kim KC, Choe SY, Hong YM. Reduced immunoreactivities of B-type
natriuretic peptide in pulmonary arterial hypertension rats after ranolazine
treatment. Anat Cell Biol. 2016 Mar;49(1):7-14. doi: 10.5115/acb.2016.49.1.7.
Epub 2016 Mar 28. PubMed PMID: 27051563; PubMed Central PMCID: PMC4819080.


9: Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart
Assoc. 2016 Mar 15;5(3). pii: e003196. doi: 10.1161/JAHA.116.003196. Review.
PubMed PMID: 26979079.


10: Greiner L, Hurren K, Brenner M. Ranolazine and Its Effects on Hemoglobin A1C.
Ann Pharmacother. 2016 Feb 25. pii: 1060028016631757. [Epub ahead of print]
Review. PubMed PMID: 26917816.


11: Redfors B, Généreux P. Ranolazine following percutaneous coronary
intervention: For whom? For what? Expert Rev Cardiovasc Ther. 2016 Feb 27:1-3.
[Epub ahead of print] PubMed PMID: 26840661.


12: Alexopoulos D, Kochiadakis G, Afthonidis D, Barbetseas J, Kelembekoglou P,
Limberi S, Spanos A, Triantafyllidis G. Ranolazine reduces angina frequency and
severity and improves quality of life: Observational study in patients with
chronic angina under ranolazine treatment in Greece (OSCAR-GR). Int J Cardiol.
2016 Feb 15;205:111-6. doi: 10.1016/j.ijcard.2015.10.180. Epub 2015 Oct 26.
PubMed PMID: 26730841.


13: Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray
L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW,
Ohman EM. Effects of Ranolazine on Angina and Quality of Life After Percutaneous
Coronary Intervention With Incomplete Revascularization: Results From the
Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Circulation. 2016 Jan 5;133(1):39-47. doi: 10.1161/CIRCULATIONAHA.115.019768.
Epub 2015 Nov 10. PubMed PMID: 26555329.


14: Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S,
Wagner S, Stathopoulou K, Söhren KD, Weinberger F, Schwedhelm E, Cuello F, Maier
LS, Eschenhagen T, Carrier L. Ranolazine antagonizes catecholamine-induced
dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects
in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovasc Res. 2016 Jan
1;109(1):90-102. doi: 10.1093/cvr/cvv247. Epub 2015 Nov 3. PubMed PMID: 26531128.


15: Aldasoro M, Guerra-Ojeda S, Aguirre-Rueda D, Mauricio MD, Vila JM, Marchio P,
Iradi A, Aldasoro C, Jorda A, Obrador E, Valles SL. Effects of Ranolazine on
Astrocytes and Neurons in Primary Culture. PLoS One. 2016 Mar 7;11(3):e0150619.
doi: 10.1371/journal.pone.0150619. eCollection 2016. PubMed PMID: 26950436;
PubMed Central PMCID: PMC4780741.


16: Mihos CG, Krishna RK, Kherada N, Larrauri-Reyes M, Tolentino A, Santana O.
The use of ranolazine in non-anginal cardiovascular disorders: A review of
current data and ongoing randomized clinical trials. Pharmacol Res. 2016
Jan;103:49-55. doi: 10.1016/j.phrs.2015.10.018. Epub 2015 Nov 4. Review. PubMed
PMID: 26546970.


17: Head SJ, Kappetein AP. Coronary artery disease: a dam in the river for
ranolazine. Lancet. 2016 Jan 9;387(10014):100-2. doi:
10.1016/S0140-6736(15)00458-4. Epub 2015 Oct 22. PubMed PMID: 26474812.


18: Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP,
Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone
GW; RIVER-PCI investigators. Ranolazine in patients with incomplete
revascularisation after percutaneous coronary intervention (RIVER-PCI): a
multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan
9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. PubMed
PMID: 26474810.


19: Calderón-Sánchez EM, Domínguez-Rodríguez A, López-Haldón J, Jiménez-Navarro
MF, Gómez AM, Smani T, Ordóñez A. Cardioprotective Effect of Ranolazine in the
Process of Ischemia-reperfusion in Adult Rat Cardiomyocytes. Rev Esp Cardiol
(Engl Ed). 2016 Jan;69(1):45-53. doi: 10.1016/j.rec.2015.02.027. Epub 2015 Jul
14. PubMed PMID: 26183665.


20: Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G,
Maniadakis N. Ranolazine for the symptomatic treatment of patients with chronic
angina pectoris in Greece: a cost-utility study. BMC Health Serv Res. 2015 Dec
18;15:566. doi: 10.1186/s12913-015-1228-y. PubMed PMID: 26684327; PubMed Central
PMCID: PMC4683812.